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Abstract 
Introduction 
Urothelial carcinoma (UC) is a malignant tumour, derived from the transi-
tional epithelium (urothelium), which most commonly forms in the bladder, 
but can also arise in the upper urinary tract. Recently, pembrolizumab (Key-
truda
®
) was approved for the treatment of patients with locally advanced or 
metastatic UC following platinum-containing chemotherapy by the Food 
and Drug Administration (FDA). Pembrolizumab is a humanised monoclo-
nal immunoglobulin (Ig) G4 antibody that blocks the interaction between 
the transmembrane programmed cell death-1 (PD-1) protein and its ligands. 
Thus, pembrolizumab potentiates T-cell responses, including anti-tumour 
responses and cancer-specific T-cells. 
Methodology 
Published and grey literature were identified by searching the Cochrane Li-
brary, CRD Database, Embase, Ovid Medline, PubMed, Internet sites and 
contacting the manufacturer. To assess the risk of bias at the study level, the 
assessment of the methodological quality of the evidence was conducted 
based on the EUnetHTA internal validity for randomised controlled trials. 
Furthermore, to stratify the magnitude of clinical benefit that can be ex-
pected from pembrolizumab, the original as well as an adapted version of 
the Magnitude of Clinical Benefit Scale developed by the European Society 
for Medical Oncology was used. 
Results of the KEYNOTE-045 trial 
Between 5 November 2014 and 13 November 2015, 542 patients were ran-
domly assigned to receive either pembrolizumab (n = 270) or investigator’s 
choice of chemotherapy (n = 272). After the early termination of the trial 
(second interim analysis), the co-primary endpoint overall survival (OS) was 
statistically significantly longer in the total as well as in the PD-L1 ≥10% 
population; with a gain in median OS of 2.9 and 2.8 months in the total and 
PD-L1 ≥10% population, respectively. Moreover, the objective response rate 
(ORR) was also statistically significantly higher in the pembrolizumab 
group; however, the duration of progression-free survival (PFS) did not dif-
fer between treatment groups. Treatment-related adverse events (AEs) of 
any grade, as well as of grades 3–5, were more common in control group. The 
most frequent treatment-related AEs of any grade in the pembrolizumab 
arm were pruritus, fatigue and nausea. However, patient-reported outcomes, 
like quality of life (QoL), are only available in abstract form. 
Conclusion 
Overall, the treatment with pembrolizumab offers a statistically significant 
improvement in OS, independent of the PD-L1 status, with a superior safety 
profile compared to chemotherapy at high costs. However, due to the early 
termination of the trial, a systematic overestimation of the treatment effect 
of pembrolizumab is possible, leading to a need of long-term data. In addi-
tion, the identification of a robust predictive biomarker to identify the most 
suitable patients will be crucial in the future. Finally, head-to-head compar-
ison trials comparing pembrolizumab to nivolumab and atezolizumab are 
essential to investigate which second-line treatment option UC patients ben-
efit the most from.  
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1 Research questions 
The HTA Core Model
®
 for Rapid Relative Effectiveness Assessment of 
Pharmaceuticals was used for structuring this report [1]. The Model organ-
ises HTA information according to pre-defined generic research questions. 
Based on these generic questions, the following research questions were an-
swered in the assessment. 
 
Element ID Research question 
Description of the technology 
B0001 What is pembrolizumab? 
A0022 Who manufactures pembrolizumab? 
A0007 What is the target population in this assessment? 
A0020 For which indications has pembrolizumab received marketing authorisation? 
Health problem and current use 
A0002 What is urothelial carcinoma? 
A0004 What is the natural course of urothelial carcinoma? 
A0006 What are the consequences of urothelial carcinoma for the society? 
A0023 How many people belong to the target population? 
A0005 What are the symptoms and the burden of urothelial carcinoma? 
A0003 What are the known risk factors for urothelial carcinoma? 
A0024 
How is urothelial carcinoma currently diagnosed according to published guidelines and in 
practice? 
A0025 
How is urothelial carcinoma currently managed according to published guidelines and in 
practice? 
Clinical effectiveness 
D0001 What is the expected beneficial effect of pembrolizumab on mortality? 
D0005 
How does pembrolizumab affect symptoms and findings (severity, frequency) of 
urothelial carcinoma? 
D0006 How does pembrolizumab affect progression (or recurrence) of urothelial carcinoma? 
D0011 What is the effect of pembrolizumab on patients ̕ body functions? 
D0012 What is the effect of pembrolizumab on generic health-related quality of life? 
D0013 What is the effect of pembrolizumab on disease-specific quality of life? 
Safety 
C0008 How safe is pembrolizumab in relation to the comparator(s)? 
C0002 Are the harms related to dosage or frequency of applying pembrolizumab? 
C0005 
What are the susceptible patient groups that are more likely to be harmed through the 
use of pembrolizumab? 
A0021 What is the reimbursement status of pembrolizumab? 
 
 
 
 
EUnetHTA 
HTA Core Model® 
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2 Drug description 
Generic/Brand name/ATC code:  
Pembrolizumab/Keytruda
®
/L01XC18 
 
B0001: What is pembrolizumab? 
Pembrolizumab is a humanised monoclonal immunoglobulin (Ig) G4 anti-
body that blocks the interaction between the transmembrane programmed 
cell death-1 (PD-1) protein, which is expressed on the cell surface of activat-
ed T-cells, and its ligands PD-L1 and PD-L2 [2-5]. The PD-1 receptor, a 
negative T-cell activity regulator, has been shown to be involved in the con-
trol of T-cell immune responses. By blocking the interaction of PD-1 and its 
ligands, pembrolizumab potentiates T-cell responses, including anti-tumour 
responses and cancer-specific T-cells [3, 5]. 
Pembrolizumab should be administered as an intravenous infusion over 30 
minutes every three weeks. In clinical trials investigating urothelial carci-
noma patients, 200 mg of pembrolizumab were administered intravenously 
every three weeks until disease progression or unacceptable toxicity [6]. For 
other indications the recommended dose for non-small cell lung cancer 
(NSCLC) that has not been previously treated with chemotherapy is 200 mg. 
For NSCLC patients who received prior chemotherapy, as well as for mela-
noma patients, the recommend dose is 2 mg/kg [3].  
 
A0022: Who manufactures pembrolizumab? 
Merck Sharp & Dohme Corp. 
 
 
 
3 Indication 
A0007: What is the target population in this assessment? 
Pembrolizumab is indicated for the second-line treatment of patients with 
advanced UC of the renal pelvis, ureter, bladder, or urethra that has re-
curred or progressed following platinum-based chemotherapy.  
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Pembrolizumab (Keytruda®) as second-line treatment for patients with advanced urothelial carcinoma (UC) 
LBI-HTA | 2017 9 
4 Current regulatory status 
A0020: For which indications has pembrolizumab received marketing au-
thorisation? 
To date, pembrolizumab is not approved for the second-line treatment of pa-
tients with UC by the European Medicines Agency (EMA). However, the 
EMA granted marketing authorisation of pembrolizumab for the following 
indications [3]: 
 as monotherapy for the treatment of patients with advanced unre-
sectable or metastatic melanoma (July 2015) 
 for the treatment of locally advanced or metastatic NSCLC pa-
tients, whose tumours express PD-L1, and who have received at 
least one prior chemotherapy regimen (July 2016) 
 as monotherapy for the first-line treatment of metastatic NSCLC 
patients, whose tumours express PD-L1 with a ≥50% tumour pro-
portion score (TPS) with no EGFR or ALK positive tumour muta-
tion (January 2017) 
 as monotherapy for the treatment of patients with relapsed or re-
fractory classical Hodgkin lymphoma (cHL), who have failed autol-
ogous stem cell transplant and brentuximab vedotin (BV), or who 
are transplant-ineligible and have failed BV (March 2017) 
 
In May 2017, the US Food and Drug Administration (FDA) approved pem-
brolizumab for the treatment of locally advanced or metastatic UC patients, 
who have disease progression during or following platinum-containing 
chemotherapy or within 12 months of neoadjuvant or adjuvant treatment 
with platinum-containing chemotherapy. Furthermore, the FDA also grant-
ed accelerated approval to pembrolizumab for the treatment of patients with 
locally advanced or metastatic UC, who are not eligible for cisplatin-
containing chemotherapy [7]. 
Moreover, pembrolizumab has also received marketing authorisation by the 
FDA for the following indications [7]: 
 for the treatment of patients with unresectable or metastatic mela-
noma (September 2014) 
 for the treatment of patients with recurrent or metastatic head and 
neck squamous cell carcinoma with disease progression on or after 
platinum-containing chemotherapy (August 2016) 
 for the treatment of patients with metastatic NSCLC 
 whose tumours have high PD-L1 expression (≥50% TPS) 
with no EGFR and ALK genomic tumour aberration, as a 
first-line therapy (October 2016) 
 whose tumours express PD-L1 (TPS ≥1%) with disease 
progression on or after platinum-containing chemotherapy 
(October 2016) 
 as a first-line therapy in combination with pemetrexed and 
carboplatin for non-squamous NSCLC (May 2017) 
not approved for UC by 
the EMA, but for several 
other indications 
FDA approval for UC 
since May 2017 
FDA approved 
indications of 
pembrolizumab 
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 for the treatment of patients with refractory cHL, or those who have 
relapsed after three or more prior lines of therapy (March 2017) 
 
 
 
5 Burden of disease 
A0002: What is urothelial carcinoma? 
The majority of cancers that form in the bladder, the renal pelvises, the ure-
ters, and the proximal urethra are UCs (also known as transitional cell carci-
nomas) that arise from the transitional epithelium (urothelium). UC is the 
predominant histologic type of all diagnosed bladder cancers in the United 
States and in Europe, where it accounts for about 90% of all bladder cancer 
cases. Therefore, the following information will focus on urothelial bladder 
cancer [8-10]. 
 
A0004: What is the natural course of urothelial carcinoma? 
UC of the bladder can either be low-grade or high-grade. In respect of low-
grade, bladder cancer recurrence after respective treatment often occurs, but 
it rarely invades the muscular wall of the bladder or spreads to other parts of 
the body. High-grade bladder cancer frequently recurs, has a high tendency 
to invade the muscular wall of the bladder and can spread to other parts of 
the body. Based on the invasion of the muscularis propria (detrusor muscle), 
a muscle of the bladder wall, bladder cancer can also be divided into muscle-
invasive and non-muscle-invasive disease [9].  
 
A0006: What are the consequences of urothelial carcinoma for the society? 
Due to the aging population and in combination with the fact that higher 
age is a main risk factor for cancer, the incidence of cancer is increasing over 
time [11]. Globally, UC of the bladder is the most frequent malignancy in-
volving the urinary system and the ninth most common malignancy world-
wide [12]. However, incidence rates are also influenced by risk factor preva-
lence of past years. Since cigarette smoking is one of the most important risk 
factors, a decrease in the cigarette smoking rate may also impact the inci-
dence rate of bladder cancer [13].  
 
A0023: How many people belong to the target population? 
In Austria, 1,427 new cases of bladder cancer were diagnosed in 2014 with a 
corresponding age standardised incidence rate for the European Standard 
Population of 17.3 cases per 100,000 persons. Moreover, around 65.0% of 
female bladder cancer patients (7.1/100,000/year) and 71.0% of male bladder 
cancer patients (31.6/100,000/year) are alive at least five years after diagno-
sis. About two-thirds of all diagnosed cases in Austria are identified in a lo-
calised tumour stage, whereas metastatic disease at the time of diagnosis ac-
counts for about 4.0% of patients. In addition, men have higher incidence 
and mortality rates; 70.5% of deaths and 76.4% of newly diagnosed cases oc-
most common form of 
UC is bladder cancer 
variable course of 
disease: 
high- or low-grade, 
muscle-invasive or 
non-muscle-invasive 
 bladder cancer 
increasing incidence  
of cancer 
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influence bladder 
incidence rate 
incidence rate of bladder 
cancer in Austria: 
17.3 per 100,000 
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curred in men [14]. The median age at diagnosis of bladder cancer is 69 
years in men and 71 in women [12].  
 
A0005: What are the symptoms and the burden of urothelial carcinoma? 
In the majority of patients with UC of the bladder, gross or microscopic 
haematuria is present. Symptoms like urinary frequency, nocturia, urgency 
and dysuria can occur less often. These presentations are more common in 
patients with carcinomas in situ [9]. Patients with upper urinary tract UCs 
may show pain symptoms due to the obstruction by the tumour [9, 15]. 
 
A0003: What are the known risk factors for urothelial carcinoma? 
Several risk factors have been identified for UC of the bladder. The most 
important risk factors are cigarette smoking and various occupational car-
cinogen exposures [12]. Other risk factors include: age, family history of 
bladder cancer and genetic mutations (men are more often affected than 
women) [9]. 
 
A0024: How is urothelial carcinoma currently diagnosed according to pub-
lished guidelines and in practice? 
The gold standard for the initial diagnosis of UC of the bladder is cystoscopy 
in combination with urine cytology to detect lesions of the upper urinary 
tract (ureter or renal pelvis) [9, 15]. To identify papillary and carcinoma in 
situ lesions, novel endoscopic imaging techniques like narrow-band imaging 
and fluorescence cystoscopy may be applied. To assess the depth of invasion 
(mucosa, submucosa and muscularis) and the histologic grade, initial stag-
ing either using biopsy or transurethral resection of the bladder tumour 
(TURBT), combined with a pelvic examination under anaesthesia, is re-
quired. To rule out secondary tumours imaging of the upper urinary tract by 
computed tomography, magnetic resonance imaging with intravenous con-
trast or retrograde ureter pyelography are performed [15].  
Since the depth of invasion (T = depth of invasion of the primary tumour) 
for patients with disease limited to the bladder is the most important prog-
nostic variable, it is integrated into the standard staging system, the tumour, 
node, metastasis (TNM) system [16]: 
 Ta: papillary (exophytic) lesions 
 Tis (carcinoma in situ): high-grade intraepithelial neoplasm with-
out invasion into subepithelial connective tissue 
 T1: invasion of the submucosa or lamina propria (usually high 
grade) 
 T2: invasion into muscle (increased probability of nodal and distant 
metastases) 
 T3: extension beyond muscle into the perivesical fat.  
 T4: extension into adjacent organs; tumours invading the prostate, 
vagina, uterus, or bowel are classified as T4a, while tumours fixed 
to the abdominal wall, pelvic wall, or other organs are classified as 
T4b 
most common 
presentation: 
gross or microscopic 
haematuria 
main risk factors: 
occupational carcinogen 
exposures & cigarette 
smoking 
gold standard for the 
initial diagnosis: 
cystoscopy 
TNM system 
incorporates the depth 
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primary tumour 
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6 Current treatment 
A0025: How is urothelial carcinoma currently managed according to pub-
lished guidelines and in practice? 
Muscle-invasive urothelial bladder cancer is generally treated by radical cys-
tectomy, removal of the bladder and/or adjacent organs and/or regional 
lymph nodes, accompanied with neoadjuvant and/or adjuvant cisplatin-
based combination chemotherapy. Combined-modality approaches, like 
maximal TURBT, radiation therapy, and concurrent chemotherapy are op-
tions for patients who are not candidates for radical cystectomy [15, 17, 18]. 
First-line platinum-based chemotherapy (e.g., gemcitabine plus cisplatin or 
a combination of methotrexate, vinblastine, doxorubicin, and cisplatin) is 
the preferred initial approach for systemic therapy in patients with metastat-
ic UC of the bladder and urinary tract. The particular chemotherapy regi-
men depends on the presence or absences of medical comorbidities (e.g., re-
nal impairment) of the patient. Thus, non-cisplatin-containing regimens 
(e.g., gemcitabine, carboplatin) may be considered in patients with comor-
bidities [15, 17, 18]. 
Current second-line treatment options include vinflunine, gemcitabine 
and/or paclitaxel, or a re-challenge with a platinum-based chemotherapy 
[17]. Three checkpoint inhibitors – nivolumab, atezolizumab and pembroli-
zumab – were recently approved by the FDA for the treatment of patients 
with locally advanced or metastatic UC, who have disease progression dur-
ing or following platinum-containing chemotherapy [15]. However, they 
have not yet received marketing authorisation for this indication in Europe. 
 
 
 
7 Evidence 
A literature search was conducted on 15 May 2017 in five databases: the 
Cochrane Library, CRD Database, Embase, Ovid Medline and PubMed. 
Search terms were “pembrolizumab”, “keytruda”, “urothelial cancer”, 
“urothelial carcinoma”, “bladder cancer” and “transitional cell carcinoma”. 
The manufacturer was also contacted and submitted six references (three of 
which had already been identified by systematic literature search). A manu-
al search identified 28 additional references (web documents and journal ar-
ticles). 
Overall, 91 references were identified. Included in this reported are:  
 KEYNOTE-045, phase III [6, 19] 
 KEYNOTE-012, phase Ib [20] 
To assess the risk of bias at the study level, the assessment of the methodo-
logical quality of the evidence was conducted based on the EUnetHTA in-
ternal validity for randomised controlled trials (RCTs) [21]. Evidence was 
assessed based on the adequate generation of the randomisation sequence, 
allocation concealment, blinding of patient and treating physician, selective 
mainstay of treatment 
of muscle-invasive 
urothelial bladder 
cancer: 
radical cystectomy 
standard 1st-line 
treatment options: 
platinum-based 
chemotherapy 
2nd-line treatment 
options: 
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systematic literature 
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additional references 
overall: 91 references 
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outcome reporting and other aspects that may increase the risk of bias. 
Study quality details are reported in Table 5 of the Appendix. 
To evaluate the magnitude of “clinically meaningful benefit” that can be ex-
pected from a new anti-cancer treatment, the Magnitude of Clinical Benefit 
Scale developed by the European Society for Medical Oncology (ESMO-
MCBS) was used [22]. Additionally, an adapted version (due to perceived 
limitations) of the ESMO-MCBS was applied [23]. Details of the magnitude 
of the clinically meaningful benefit scale are reported in Table 3. 
 
7.1 Clinical efficacy and safety –  
Phase III studies 
KEYNOTE-045 [6, 19], an open-label, international, randomised phase III 
study, was conducted to assess the efficacy and safety of pembrolizumab in 
patients with UC (renal pelvis, ureter, bladder or urethra) that has recurred 
or progressed following platinum-based chemotherapy. A total of 542 pa-
tients were randomly assigned in a 1:1 ratio to receive either pembrolizumab 
(n = 270, 200 mg) or the investigator’s choice of chemotherapy (n = 272), 
paclitaxel (175 mg/m²), docetaxel (75 mg/m²) or vinflunine (320 mg/m²) 
every three weeks. The stratification of randomisation was based on the 
Eastern Cooperative Oncology Group (ECOG) performance-status score (0 
or 1 versus 2), the presence of liver metastases (yes versus no), haemoglobin 
concentration (<10 g per decilitre versus ≥10 g per decilitre), and time 
since the last dose of chemotherapy (<3 months versus ≥3 months). Of the 
542 randomised patients, 266 patients in the pembrolizumab group and 255 
in the chemotherapy group received assigned treatment. 
The study consisted of two pre-specified interim analyses and was prema-
turely terminated after the second interim analysis (October 2016), because 
pembrolizumab met the superiority thresholds for overall survival (OS) in 
the co-primary populations. The second interim analysis was performed af-
ter 334 deaths had occurred in the total population and 104 deaths had oc-
curred in the population of patients with a tumour PD-L1 combined posi-
tive score of ≥10% (PD-L1 ≥10% population) assessed by the PD-L1 IHC 
22C3 pharmDx assay (Dako North America). 
Enrolled patients had a median age of 67 (29–88) and 65 (26–84) years in the 
pembrolizumab and chemotherapy group, respectively. The study popula-
tion had an ECOG performance status of 0–2 and had at least one measura-
ble lesion according to the Response Evaluation Criteria in Solid Tumours 
(RECIST), version 1.1. Detailed patient characteristics, including inclusion 
and exclusion criteria, are reported in Table 4. 
The co-primary outcomes of KEYNOTE-045 were OS and progression-free 
survival (PFS); secondary outcomes included objective response rate (ORR), 
the duration of confirmed response (DOR), and safety (total population). 
Adverse events (AEs) were assessed in conformity with the National Cancer 
Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, 
version 4.0).  
 
magnitude of clinically 
meaningful benefit 
assessed based on 
ESMO-MCBS 
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7.1.1 Clinical efficacy 
D0001: What is the expected beneficial effect of pembrolizumab on mortali-
ty? 
At the time of second interim analysis (7 September 2016), 334 deaths had 
occurred in the intention-to-treat population. In the total population the 
median OS was 10.3 months (95% CI 8.0–11.8) in the pembrolizumab group 
and 7.4 months (95% CI 6.1–8.3) in the chemotherapy group. OS was statis-
tically significantly longer in the pembrolizumab group (hazard ratio [HR] 
for death, 0.73; 95% CI 0.59-0.91; p = 0.002). The estimated overall survival 
rate at 12 months was 43.9% (95% CI 37.8–49.9) and 30.7% (95% CI 
25.0-36.7) in the pembrolizumab and chemotherapy group, respectively. 
In the PD-L1 ≥10% population OS was statistically significantly longer in 
the pembrolizumab group (HR for death, 0.57; 95% CI 0.37–0.88; 
p = 0.005). The median OS was 8.0 months (95% CI 5.0–12.3) in the pem-
brolizumab group compared to 5.2 months (95% CI 4.0–7.4) in the chemo-
therapy group. 
 
D0006: How does pembrolizumab affect progression (or recurrence) of 
urothelial carcinoma? 
437 events of disease progression or death have occurred in the intention-to-
treat population at the time of the second interim analysis. The median PFS 
was 2.1 months (95% CI 2.0–2.2) and 3.3 months (95% CI 2.3–3.5) in the 
pembrolizumab and chemotherapy group, respectively. There was no statis-
tically significant difference in the duration of PFS between the two study 
groups, neither in the total population (HR for death or disease progression, 
0.98; 95% CI 0.81–1.19; p = 0.42) nor in the PD-L1 ≥10% population 
(HR, 0.89; 95% CI 0.61–1.28; p = 0.24). The estimated PFS rate at 12 
months was 16.8% (95% CI 12.3-22.0) in the pembrolizumab group com-
pared to 6.2% (95% CI 3.3-10.2) in the chemotherapy group. 
 
D0005: How does pembrolizumab affect symptoms and findings (severity, 
frequency) of urothelial carcinoma? 
The ORR was statistically significantly higher in the pembrolizumab group 
compared to the chemotherapy group, 21.1% (95% CI 16.4–26.5) versus 
11.4% (95% CI 7.9–15.8), (p = 0.001). In both study groups the median time 
to response was 2.1 months. At the time of the second interim analysis, 41 of 
57 patients (72.0%) showed a continued response in the pembrolizumab 
group and 11 of 31 patients (35.0%) had a continued response in the chemo-
therapy group. In the pembrolizumab group the median duration of re-
sponse (DOR) was not reached, while in the chemotherapy group it was 4.3 
months. The estimated DOR of at least 12 months was 68.0% of patients in 
the pembrolizumab group and 35.0% in the chemotherapy group. 
 
D0011: What is the effect of pembrolizumab on patients̕ body functions? 
Pembrolizumab may affect body functions by causing immune-mediated 
AEs including pneumonitis, hepatitis, colitis, endocrinopathies, nephritis 
and renal dysfunction. In addition, since pembrolizumab is a therapeutic 
protein, there is a potential for immunogenicity [7]. 
median OS gain: 
2.9 months 
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longer OS in the PD-L1 
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no statistically 
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the duration of PFS 
statistically significant 
difference in ORR 
 
ORR gain: 
9.7% 
immune-mediated AEs, 
potential 
immunogenicity 
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D0012: What is the effect of pembrolizumab on generic health-related quali-
ty of life? 
D0013: What is the effect of pembrolizumab on disease-specific quality of 
life? 
Currently, quality of life (QoL) data is only available in abstract form [24]. 
Pembrolizumab was associated with a consistently better health-related 
quality of life compared to the investigator’s choice of paclitaxel, docetaxel, 
or vinflunine. The global health status was similar between the arms. Re-
garding time to deterioration in the global health status, a prolonged score 
with pembrolizumab compared to chemotherapy was shown (HR 0.70, p = 
0.002). 
 
 
Table 1: Efficacy results of the KEYNOTE-045 trial 
Descriptive statis-
tics and estimated 
variability 
Treatment group Pembrolizumab Chemotherapy 
Number of subjects 270 272 
Median OS, months (95% CI) 10.3 (8.0–11.8) 7.4 (6.1–8.3) 
Median OS (PD-L1 ≥10%),  
months (95% CI) 
8.0 (5.0–12.3) 5.2 (4.0–7.4) 
Median PFS, months (95% CI) 2.1 (2.0–2.2) 3.3 (2.3–3.5) 
ORR, % (95% CI) 21.1 (16.4–26.5) 11.4 (7.9–15.8) 
Median DOR, months NR 4.3 
QoL NA NA 
Effect estimate per 
comparison 
 
Comparison groups 
Pembrolizumab vs. 
Chemotherapy 
OS HR 0.73 
95% CI 0.59–0.91 
Log-rank test p value 0.002 
OS (PD-L1 ≥10%) HR 0.57 
95% CI 0.37–0.88 
Log-rank test p value 0.005 
PFS 
 
HR 0.98 
95% CI 0.81–1.19 
Log-rank test p value 0.42 
Abbreviations: CI = confidence interval, HR = hazard ratio, DOR = duration of response, NA = not available, NR = 
not reached, ORR = objective response rate, OS = overall survival, PFS = progression-free survival, QoL = quality of 
life 
 
 
 
 
results on QoL only 
available in abstract 
form 
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7.1.2 Safety 
C0008: How safe is pembrolizumab in relation to the comparator(s)? 
AEs of any grade related to treatment were reported from 60.9% (pembroli-
zumab) and 90.2% (chemotherapy) of the patients. The most frequent 
treatment-related AEs of any grade were pruritus (19.5%), fatigue (13.9%) 
and nausea (10.9%) in the pembrolizumab group and alopecia (37.6%), fa-
tigue (27.8%) and anaemia (24.7%) in the chemotherapy group.  
Grade ≥3 treatment-related events occurred less frequently in the pembroli-
zumab group compared to the chemotherapy group (15.0% versus 49.4% of 
patients), as well as treatment-related discontinuation, 5.6% versus 11.0%. 
In the pembrolizumab group, no treatment-related AEs of grade 3 or higher 
have occurred with an incidence of ≥5%. The most common treatment-
related grade ≥3 AEs, with an incidence of ≥5% in the chemotherapy 
group, were neutropenia (13.3%), decreased neutrophil count (12.2%), 
anaemia (7.8%), febrile neutropenia (7.1%), and decreased white-cell count 
(5.1%). 
In total, eight deaths were attributed to either chemotherapy or pembroli-
zumab. Out of those eight deaths, four occurred in the pembrolizumab 
group either due to pneumonitis, a urinary tract obstruction, a malignant 
neoplasm progression, or an unspecified cause. 
 
C0002: Are the harms related to dosage or frequency of applying 
pembrolizumab? 
No evidence was found to answer this research question. 
 
C0005: What are the susceptible patient groups that are more likely to be 
harmed through the use of pembrolizumab? 
Pembrolizumab may impair fertility and cause foetal harm, resulting in ma-
jor birth defects or miscarriages, due to its mechanism of action. It is ad-
vised that females use effective contraception during the treatment with 
pembrolizumab and discontinue breast feeding for at least four months fol-
lowing the final dosage [7]. 
 
any grade AEs 
pembrolizumab: 60.9% 
chemotherapy: 90.2% 
 
grade 3-5 AEs 
pembrolizumab: 15.0% 
chemotherapy: 49.4% 
4 treatment-related 
deaths in the 
pembrolizumab group 
pregnant or breast-
feeding women 
susceptible, due to 
potential foetal harm 
and impaired fertility 
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Table 2: Most frequent treatment-related adverse events
1
 
 
Adverse event (according  
to NCI-CTC version 4.0) 
 
Pembrolizumab 
(n = 266) 
Chemotherapy group 
(n = 255) 
 Any grade 
n (%) 
Grade ≥3 
n (%) 
Any grade 
n (%) 
Grade ≥3 
n (%) 
Treatment-related event 
Any event 162 (60.9) 40 (15.0) 230 (90.2) 126 (49.4) 
Event leading to discontinuation of treatment 15 (5.6) 12 (4.5) 28 (11.0) 16 (6.3) 
Event leading to death 4 (1.5) 4 (1.5) 4 (1.6) 4 (1.6) 
Event occurring in ≥10% of patients in either group 
Pruritus 52 (19.5) 0 (0) 7 (2.7) 1 (0.4) 
Fatigue 37 (13.9) 3 (1.1) 71 (27.8) 11 (4.3) 
Nausea 29 (10.9) 1 (0.4) 62 (24.3) 4 (1.6) 
Diarrhoea 24 (9.0) 3 (1.1) 33 (12.9) 2 (0.8) 
Decreased appetite 23 (8.6) 0 (0) 41 (16.1) 3 (1.2) 
Asthenia  15 (5.6) 1 (0.4) 36 (14.1) 7 (2.7) 
Anaemia 9 (3.4) 2 (0.8) 63 (24.7) 20 (7.8) 
Constipation 6 (2.3) 0 (0) 52 (20.4) 8 (3.1) 
Peripheral sensory neuropathy 2 (0.8) 0 (0) 28 (11.0) 5 (2.0) 
Neutrophil count decreased 1 (0.4) 1 (0.4) 36 (14.1) 31 (12.2) 
Peripheral neuropathy 1 (0.4) 0 (0) 27 (10.6) 2 (0.8) 
Neutropenia 0 (0) 0 (0) 39 (15.3) 34 (13.3) 
Alopecia 0 (0) 0 (0) 96 (37.6) 2 (0.8) 
Event of interest 
Any event 45 (16.9) 12 (4.5) 19 (7.5) 4 (1.6) 
Hypothyroidism 17 (6.4) 0 (0) 3 (1.2) 0 (0) 
Hyperthyroidism 10 (3.8) 0 (0) 1 (0.4) 0 (0) 
Pneumonitis 11 (4.1) 6 (2.3) 1 (0.4) 0 (0) 
Colitis 6 (2.3) 3 (1.1) 1 (0.4) 0 (0) 
Infusion reaction 2 (0.8) 0 (0) 10 (3.9) 0 (0) 
Nephritis 2 (0.8) 2 (0.8) 0 (0) 0 (0) 
Severe skin reaction 2 (0.8) 1 (0.4) 3 (1.2) 3 (1.2) 
Thyroiditis 2 (0.8) 0 (0) 0 (0) 0 (0) 
Adrenal insufficiency 1 (0.4) 1 (0.4) 0 (0) 0 (0) 
Myositis 0 (0) 0 (0) 1 (0.4) 1 (0.4) 
Abbreviations: AEs = adverse events, NCI-CTC = National Cancer Institute Common Terminology Criteria for Adverse Events 
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7.2 Clinical effectiveness and safety –  
Further studies 
A non-randomised, multi-cohort, open-label phase Ib trial [20] was conduct-
ed to assess the safety and activity of pembrolizumab in patients with locally 
advanced or metastatic UC. All patients (115) were pre-screened and were 
required to have at least 1.0% PD-L1 expression detected on the tumour 
cells or in tumour stroma, as determined by immunohistochemistry. 61 
(53.0%) were PD-L1 positive, of whom 33 were enrolled in the study and 27 
comprised the full analysis set. Every two weeks patients received a dose of 
10 mg/kg of intravenous pembrolizumab. The primary endpoints were safe-
ty and overall response (OR, defined by RECIST, version 1.1) assessed by a 
masked, independent central review. 
The most frequent treatment-related AEs of any grade were fatigue (six 
[18.0%] of 33 patients) and peripheral oedema (four [12.0%]). Treatment-
related grade 3 AEs occurred in five (15.0%) patients and serious treatment-
related AEs were experienced in three (9.0%) patients. An OR was achieved 
in seven patients (26.0%), of whom three showed a complete response and 
four a partial response after a median follow-up of 13 months. In total, four 
deaths occurred during the study, due to cardiac arrest, pneumonia, sepsis 
and subarachnoid haemorrhage; none of those were considered as treatment-
related. 
 
 
 
8 Estimated costs 
A0021: What is the reimbursement status of pembrolizumab? 
In Austria, pembrolizumab is available as 25 mg and 50 mg concentrated in-
fusion solutions. The ex-factory price of 100 mg is € 3,428; therefore, based 
on a dose of 200 mg every three weeks, costs of € 6,856 per treatment cycle 
would incur [25]. 
 
 
 
9 Ongoing research 
In June 2017, a search in databases www.clinicaltrials.gov and 
https://www.clinicaltrialsregister.eu/ was conducted. One ongoing phase III 
trial investigating pembrolizumab in UC was identified: 
 NCT02853305: A phase III randomised controlled clinical trial of 
pembrolizumab with or without platinum-based combination 
chemotherapy versus chemotherapy in subjects with advanced or 
KEYNOTE-012: 
safety and activity in 
locally advanced or 
metastatic PD-L1 
positive UC patients 
most common AEs: 
fatigue & peripheral 
oedema 
 
OR in 26.0% of patients 
estimated costs per 
treatment cycle: € 6,856 
1 ongoing phase III study 
investigating 
pembrolizumab in UC 
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metastatic urothelial carcinoma. Estimated study completion date 
is March 2020. 
Various phase I and II studies are currently ongoing in different treatment 
lines in patients with UC, either using pembrolizumab monotherapy or 
combination treatment (e.g., NCT02351739, NCT02335424, NCT02717156, 
NCT02621151, and NCT02437370). In addition, pembrolizumab is also cur-
rently being investigated in other indications, like hepatocellular carcinoma, 
colon cancer, breast cancer, pancreatic cancer and renal cell cancer. 
 
 
 
10 Discussion 
Since May 2017, pembrolizumab has been approved by the FDA for the 
treatment of locally advanced or metastatic UC patients, who have disease 
progression during or following platinum-containing chemotherapy or with-
in 12 months of neoadjuvant or adjuvant treatment with platinum-
containing chemotherapy [7]. In Europe pembrolizumab has not yet re-
ceived marketing authorisation for the treatment of UC, but for several oth-
er indications [3]. 
The FDA approval was based on an open-label, international, randomised 
phase III study, the KEYNOTE-045 trial [6, 19]. The study was conducted to 
assess the efficacy and safety of pembrolizumab in 542 patients with UC that 
have recurred or progressed following platinum-based chemotherapy. After 
the early termination of the trial (second interim analysis), OS was statisti-
cally significantly longer in the total as well as in the PD-L1 ≥10% popula-
tion, with a gain in median OS of 2.9 and 2.8 months in the total and PD-L1 
≥10% population, respectively. There was no statistically significant differ-
ence in the duration of PFS between the two study groups, neither in the to-
tal nor in the PD-L1 ≥10% population. However, the ORR in the total pop-
ulation was statistically significantly higher in the pembrolizumab group 
compared to the chemotherapy group (+9.7%). 
A statistically significantly prolonged OS was shown across all subgroups 
analyses, except for patients who had no smoking history. Therefore, addi-
tional investigations are necessary in order to exclude any disadvantages for 
the non-smoking patient population – especially since similar trends for this 
patient population are available in trials investigating immune checkpoint 
inhibitors in NSCLC [26-28]. 
In terms of safety, treatment-related AEs of any grade, as well as of grades 3–
5, were more common in the chemotherapy group than in the pembroli-
zumab group. The most frequent treatment-related AEs of any grade in the 
pembrolizumab arm were pruritus, fatigue and nausea. The discontinuation 
rate was also higher in the chemotherapy group compared to the pembroli-
zumab group (5.6% versus 11.0%). Patient-reported outcomes, like QoL, 
were only available in abstract form. 
Although data regarding QoL is currently available in abstract form [24] and 
pembrolizumab causes fewer side effects than the investigator’s choice of 
numerous ongoing 
phase I and II trials in 
different indications and 
treatment lines 
indication approved by 
the FDA, but not yet by 
the EMA 
KEYNOTE-045: early 
termination after 
second interim analysis 
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PD-L1 ≥10% population 
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treatment-related AEs 
of any grade & grade 3–5 
less common in the 
pembrolizumab group 
sparse evidence about 
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chemotherapy (paclitaxel, docetaxel, or vinflunine), more evidence is needed 
to ensure a favourable benefit for patients treated with pembrolizumab.  
Besides that, the early termination of the KEYNOTE-045 can lead to a sys-
tematic overestimation of the treatment effect of pembrolizumab [29]. 
Therefore, a low level of evidence of the benefit of pembrolizumab exists, 
which cannot be translated into clinical practice without further confirma-
tive trials [30]. In general, there are several methodological limitations of the 
KEYNOTE-045 study. No evidence was available on the generation of ran-
domisation sequence as well as on the allocation concealment, which may 
lead to a selection bias. Furthermore, since it is an open-label study – pa-
tients and treating physicians are aware of the treatment a patient receives - 
the probability of a performance as well as a detection bias is given. Howev-
er, an external data and safety monitoring committee assessed efficacy and 
safety at the time of pre-specified interim analyses and subsequently may act 
against these biases. 
Given the non-curative treatment setting of pembrolizumab and the statisti-
cally significant co-primary endpoint OS, we applied Form 2a of the ESMO-
MCBS in order to assess whether pembrolizumab satisfies the criteria for a 
“meaningful clinical benefit” (score 4 or 5). Both the original as well as the 
adapted version of the MCBS were applied [22, 23]. The application of the 
ESMO-MCBS to the KEYNOTE-045 study resulted in a grade 4 and 3 in the 
original and the adapted version of the ESMO-MCBS, respectively. There-
fore, pembrolizumab only leads to a meaningful clinical benefit in the origi-
nal scale, but not in the adapted framework. This difference occurs due to 
the use of the point estimate of the HR in the adapted framework instead of 
the lower limit of the HR in the original version. 
Since 230 (42.4%) patients of the study were younger than 65 years and the 
median age at diagnosis of bladder cancer is 69 years in men and 71 in wom-
en, the study population reflected younger patients than those common in 
clinical practice. In addition, only 6 (1.1%) patients had an ECOG perfor-
mance-status score of 2. A gain of 2.9 months in median OS was observed 
not only in a younger, but also in a less diseased population (ECOG 0–1), 
and might not be reached in the general patient population. Therefore, this 
patient population should be further analysed in future trials to identify any 
advantages or disadvantages for less fit patients when treated with pembroli-
zumab. 
Moreover, there is no standard value that is termed as a positive PD-L1 sta-
tus. Consequently, the cut-off levels of the PD-L1 status may have an influ-
ence on response rates and limit comparability of trial results investigating 
PD-L1 inhibitors [31]. In the KEYNOTE-045 trial, OS was statistically sig-
nificantly prolonged in both investigated study populations (total and PD-
L1 ≥10% population). Since the PD-L1 status had no major effect on the re-
sults of the study, it would be crucial to identify a more reliable predictive 
biomarker to select those patients who benefit most from pembrolizumab 
[31-33]. 
Two other PD-L1 inhibitors (nivolumab and atezolizumab) are already ap-
proved in the US for the treatment of patients with UC [34, 35]. In addition, 
the Committee for Medicinal Products for Human Use (CHMP) adopted a 
positive opinion recommending nivolumab for the treatment of UC in Eu-
rope [36]. Direct comparisons of pembrolizumab to these immune check-
point inhibitors would therefore be important in order to identify the best 
high risk of bias: 
unclear allocation 
concealment 
&generation of 
randomisation 
sequence, 
open-label, 
early termination 
ESMO-MCBS 
original: grade 4 
adapted: grade 3 
age of the study 
population was not 
representative for the 
actual patient 
population 
robust biomarker is 
needed for a better 
patient selection 
direct comparisons of 
pembrolizumab to 
nivolumab & 
atezolizumab 
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treatment option for UC patients after failure of prior platinum-containing 
therapy.  
The costs of one pembrolizumab (200 mg every three weeks) treatment cycle 
are approximately € 6,850; for a treatment duration of six weeks (two treat-
ment cycles) costs of about € 13,700 would occur. On the other hand, the cost 
per six weeks for the treatment of UC with nivolumab is about € 12,700 [25]. 
Since atezolizumab has not been approved yet in Europe, no price estimates 
are available. Thus, one treatment cycle of nivolumab would be slightly less 
expensive than one treatment cycle of pembrolizumab. However, additional 
costs for the treatment of side effects, possible future biomarkers and in the 
in/outpatient sector will incur. For that reason, a direct comparison of 
nivolumab and pembrolizumab is recommended to identify the costs in rela-
tion to the efficacy.  
In conclusion, the treatment with pembrolizumab offers a statistically sig-
nificant improvement in OS of 2.9 months, independent of the PD-L1 sta-
tus, with a superior safety profile compared to chemotherapy at high costs. 
Due to the early termination of the trial, though, a systematic overestima-
tion of the treatment effect of pembrolizumab is possible, leading to a need 
of long-term data. In addition, the identification of a robust predictive bi-
omarker to identify the most suitable patients will be crucial in the future. 
Finally, the direct comparison of pembrolizumab to nivolumab and atezoli-
zumab is essential to investigate which treatment option UC patients benefit 
the most from. 
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Table 3: Benefit assessment based on original ESMO-MCBS and adapted benefit assessment based on adapted ESMO-MCBS 
ESMO-
MCBS 
Active  
substance Indication Intention PE Form 
MG standard 
treatment 
Efficacy Safety 
AJ FM 
MG months 
HR 
(95% CI) 
Score calculation PM Toxicity QoL 
Adapted 
ESMO-
MCBS 
Pembrolizumab 
UC 
(2nd-line) 
Not 
curative OS 2a ≤1 year +2.9 
0.73 
0.59–0.91 
HR >0.65-0.70 OR  
Gain 1.5–2.4 months 
2 
-34.4% grade  
3–4 AEs (+1) - +1
A 3 
Original 
ESMO-
MCBS 
Pembrolizumab UC 
(2nd-line) 
Not 
curative 
OS 2a ≤1 year +2.9 
0.73 
0.59–0.91 
HR ≤0.65 AND  
Gain 2.5–2.9 months 
4 x - x 4 
Abbreviations: AJ = Adjustments, CI = confidence interval, FM = final adjusted magnitude of clinical benefit grade, HR = hazard ratio, m = months, MG = median gain, ND = no difference, OS = overall survival, PE = prima-
ry endpoint, PM = preliminary magnitude of clinical benefit grade, QoL = quality of life, UC = urothelial cancer 
 
DISCLAIMER 
The scores achieved with the ESMO Magnitude of Clinical Benefit Scale are influenced by several factors: by the specific evaluation form used, by the confidence interval (CI) of the endpoint 
of interest, and by score adjustments due to safety issues. Ad form: Every individual form measures a different outcome. The meaning of a score generated by form 2a is not comparable to the 
exact same score resulting from the use of form 2c. To ensure comparability, we report the form that was used for the assessment. Ad CI: The use of the lower limit of the CI systematically fa-
vours drugs with a higher degree of uncertainty (broad CI). Hence, we decided to avoid this systematic bias and use the mean estimate of effect. Ad score adjustments: Cut-off values and out-
comes that lead to an up- or downgrading seem to be arbitrary. In addition, they are independent of the primary outcome and, therefore, a reason for confounding. Hence, we report the adjust-
ments separately. 
 
 
                                                             
A
 Downgrade due to a negative difference of at least 10% in grade ≥3 AEs 
Pembrolizumab (Keytruda®) as second-line treatment for patients with advanced urothelial carcinoma (UC) 
LBI-HTA | 2017 23 
11 References 
[1]   European Network for Health Technology Assessment (EUnetHTA). HTA Core Model
®
 for Rapid Relative 
Effectiveness Assessment of Pharmaceuticals.Version 3.0. 2013 [cited 2017-05-16]; Available from: 
http://meka.thl.fi/htacore/model/HTA%20Core%20Model%20for%20Rapid%20REA%20of%20Pharmac
euticals%203.0.pdf. 
[2]   Farina MS, Lundgren KT, Bellmunt J. Immunotherapy in Urothelial Cancer: Recent Results and Future 
Perspectives. Drugs. 2017. 
[3]   European Medicines Agency. European Puplic Assessment Report (EPAR) - Prembolizumab. 2017 [cited 
2017-05-16]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/003820/WC500190990.pdf. 
[4]   Festino L, Botti G, Lorigan P, Masucci GV, Hipp JD, Horak CE, et al. Cancer Treatment with Anti-PD-1/PD-
L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection? Drugs. 2016;76(9):925-45. 
[5]   Nihr H, Ludwig Boltzmann Institut fuer Health Technology A. Pembrolizumab (Keytruda) for advanced or 
metastatic urothelial cancer – second line Pembrolizumab (Keytruda®) for the treatment of advanced 
melanoma. Birmingham Vienna: NIHR Horizon Scanning Research&Intelligence Centre Ludwig Boltzmann 
Institut fuer Health Technology Assessment (LBIHTA); 2015. 
[6]   Bellmunt J, De Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second-line therapy for 
advanced urothelial carcinoma. New England Journal of Medicine. 2017;376(11):1015-26. 
[7]   U.S. Food and Drug Administration. Drugs@FDA. Keytruda
®
. Label information. 2017 [cited 2017-05-22]; 
Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125514s017s018lbl.pdf. 
[8]   Bellmunt J. Treatment of metastatic urothelial cancer of the bladder and urinary tract. In: Raghavan D, 
Michael ER, editors. UpToDate. Waltham, MA. (cited 22.05.2017): UpToDate; 2017. 
[9]   National Cancer Institute. Bladder Cancer Treatment (PDQ
®
)–Health Professional Version. 2017 [cited 2017-
05-23]; Available from: https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq. 
[10]   National Cancer Institute. Bladder and Other Urothelial Cancers Screening (PDQ
®
)–Patient Version. 2016 
[cited 2017-05-22]; Available from: https://www.cancer.gov/types/bladder/patient/bladder-screening-
pdq#section/_28. 
[11]   Berger N, Savvides P, Koroukian S, Kahana EF, Deimling GT, Rose JH, et al. Cancer in the Elderly. 
Transactions of the American Clinical and Climatological Association. 2006;117:147-56. 
[12]   Daneshmand S. Epidemiology and risk factors of urothelial (transitional cell) carcinoma of the bladder. In: 
Raghavan D, Ross ME, editors. UpToDate. Waltham, MA. (cited 23.05.2017): UpToDate; 2016. 
[13]   Cancer Research UK. Bladder cancer incidence statistics.  [cited 2017-05-23]; Available from: 
http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bladder-
cancer/incidence#heading-Two. 
[14]   STATISTIK AUSTRIA. Harnblase. Krebsinzidenz & Krebsmortalität.  [cited 2017-05-22]; Available from: 
https://www.statistik.at/web_de/statistiken/menschen_und_gesellschaft/gesundheit/krebserkrankungen/
harnblase/index.html. 
[15]   Lerner SP, Raghavan M. Overview of the initial approach and management of urothelial bladder cancer. In: 
Richie JP, Ross ME, editors. UpToDate. Waltham, MA. (cited 24.05.2017): UpToDate; 2016. 
[16]   Brierley J. D., Gospodarowicz M. K., Wittekind C. TNM Classification of Malignant Tumours, 8th Edition. 
2016. 
[17]   AWMF online. Das Portal der wissenschaftlichen Medizin. Früherkennung, Diagnose, Therapie und 
Nachsorge des Harnblasenkarzinoms. 2016 [cited 2017-05-29]; Available from: 
http://www.awmf.org/uploads/tx_szleitlinien/032-038ol_k_S3_Harnblasenkarzinom_2016-12.pdf. 
Horizon Scanning in Oncology 
24 LBI-HTA | 2017 
[18]   Network NCC. NCCN Guidelines Version 5.2017 - Bladder Cancer. 2017 [cited 2017-05-29]; Available from: 
https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. 
[19]   Bellmunt J, De Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second-line therapy for 
advanced urothelial carcinoma - supplementary material. New England Journal of Medicine. 
2017;376(11):1015-26. 
[20]   Plimack ER, Bellmunt J, Gupta S, Berger R, Chow LQM, Juco J, et al. Safety and activity of pembrolizumab 
in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-
label, phase 1b study. The Lancet Oncology. 2017;18(2):212-20. 
[21]   EUnetHTA - European network for Health Technology Assessment. Internal validity of randomized 
controlled trials 2013 [cited 2017-05-16]; Available from: https://eunethta.fedimbo.belgium.be/sites 
/5026.fedimbo.belgium.be/files/Internal_Validity.pdf. 
[22]   Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, et al. A standardised, generic, validated 
approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: The 
European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Annals of 
Oncology. 2015. 
[23]   Wild C, Grössmann N, Bonanno PV, Bucsics A, Furst J, Garuoliene K, et al. Utilisation of the ESMO-MCBS 
in practice of HTA. Annals of Oncology. 2016. 
[24]   Vaughn DJ, Bellmunt J, De Wit R, Fradet Y, Lee J-L, Fong L, et al. Health-related quality of life (HRQoL) in 
the KEYNOTE-045 study of pembrolizumab versus investigator-choice chemotherapy for previously treated 
advanced urothelial cancer. Journal of Clinical Oncology. 2017;35(6_suppl):282-. 
[25]   Warenverzeichnis Apothekerverlag Online. 2017 [cited 2017-06-02]; Available from: 
http://warenverzeichnis.apoverlag.at/. 
[26]   Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus Docetaxel in 
Advanced Nonsquamous Non–Small-Cell Lung Cancer. New England Journal of Medicine. 
2015;373(17):1627-39. 
[27]   Johnson DB, Rioth MJ, Horn L. Immune Checkpoint Inhibitors in NSCLC. Current treatment options in 
oncology. 2014;15(4):658-69. 
[28]   Grigg C, Rizvi NA. PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction? Journal for 
immunotherapy of cancer. 2016;4:48. 
[29]   Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, et al. Stopping randomized trials early for 
benefit and estimation of treatment effects: systematic review and meta-regression analysis. Jama. 
2010;303(12):1180-7. 
[30]   Trotta F, Apolone G, Garattini S, Tafuri G. Stopping a trial early in oncology: for patients or for industry? 
Annals of Oncology. 2008;19(7):1347-53. 
[31]   Aoun F, Rassy EE, Assi T, Albisinni S, Katan J. Advances in urothelial bladder cancer immunotherapy, dawn 
of a new age of treatment. Immunotherapy. 2017;9(5):451-60. 
[32]   Mitchell F. Pembrolizumab as second-line treatment for urothelial cancer. The Lancet Oncology. 
2017;18(4):e197. 
[33]   Morales-Barrera R, Suarez C, de Castro AM, Racca F, Valverde C, Maldonado X, et al. Targeting fibroblast 
growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New 
direction and New Hope. Cancer treatment reviews. 2016;50(cnn, 7502030):208-16. 
[34]   U.S. Food and Drug Administration. Nivolumab for Treatment of Urothelial Carcinoma. 2017 [cited 2017-06-
06]; Available from: https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm539646.htm. 
[35]   U.S. Food and Drug Administration. Atezolizumab for Urothelial Carcinoma. 2017 [cited 2017-06-06]; 
Available from: https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm501878.htm. 
Pembrolizumab (Keytruda®) as second-line treatment for patients with advanced urothelial carcinoma (UC) 
LBI-HTA | 2017 25 
[36]   European Medicines Agency. Pending EC decision - Opdivo. 2017 [cited 2017-06-06]; Available from: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003985/smops/Positi
ve/human_smop_001119.jsp&mid=WC0b01ac058001d127. 
 
  
Horizon Scanning in Oncology 
26 LBI-HTA | 2017 
12 Appendix  
Table 4: Characteristics of the KEYNOTE-045 trial 
Title: Pembrolizumab as second-line therapy for advanced urothelial carcinoma [6, 19] 
Study identifier NCT02256436, EudraCT number 2014-002009-40, KEYNOTE-045 
Design Phase III, randomised, international, open-label trial 
Duration Two pre-specified interim analyses. Termination (October 
2016) after the second interim analysis, cut-off date 7 Sep-
tember 2016. 
Hypothesis 
Superiority 
The study was designed to show a prolonged OS (HR 0.781) in patients treated with pembroli-
zumab compared to those who received investigator´s choice of chemotherapy. The planned sam-
ple size of the study was 470 patients to provide 88% power at a one-sided 2.5% significance level 
in the total population and 86% power to show a HR of 0.625 in the PD-L1 ≥10% population. 
Funding Merck Sharp & Dohme Corp. 
Treatments groups 
 
Intervention (n = 270) 200 mg pembrolizumab IV every three weeks 
Control (n = 272) 
Investigator’s choice of chemotherapy, every three weeks 
either paclitaxel: 175 mg/m², docetaxel: 75 mg/m² or vin-
flunine: 320 mg/m². 
Endpoints and definitions 
 
Overall survival 
(co-primary outcome) 
OS time from randomisation to death from any cause 
Progression-free survival 
(co-primary outcome) 
PFS time from randomisation to disease progression or death from any cause per RECIST 1.1 
Objective response rate ORR 
percentage of patients who had a confirmed response de-
fined as the time from the first documented complete or 
partial response to disease progression or death, per RE-
CIST 1.1 
Duration of confirmed re-
sponse DOR 
time from the first documented complete or partial re-
sponse to disease progression or death 
Database lock Last updated: 6 April 2017 
Results and Analysis  
 
Analysis description Primary Analysis 
Efficacy analyses were performed in the intention-to-treat population (all patients who were as-
signed to a treatment group); safety was assessed in the as-treated population (all patients who 
received at least one dose of study treatment). OS and PFS were analysed by a stratified log-rank 
test; HRs and associated 95% CIs were calculated with the use of a stratified Cox proportional-
hazards model and Ephron’s method of handling ties. 
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Title: Pembrolizumab as second-line therapy for advanced urothelial carcinoma [6, 19] 
Study identifier NCT02256436, EudraCT number 2014-002009-40, KEYNOTE-045 
Analysis population 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inclusion  Age ≥ 18 years 
 Histologically or cytologically confirmed diagnosis of UC of the renal pelvis, 
ureter, bladder, or urethra, that is a transitional cell or mixed transition-
al/non-transitional (predominantly transitional) cell type 
 Progression or recurrence of UC following a first-line platinum-containing 
regimen (e.g., cisplatin, carboplatin) for metastatic or inoperable locally ad-
vanced disease; or adjuvant platinum-based therapy following cystectomy for 
localised muscle-invasive UC with recurrence/progression ≤12 months follow-
ing completion of therapy; or neoadjuvant platinum-containing therapy prior 
to cystectomy for localised muscle-invasive UC with recurrence ≤12 months 
following completion of therapy 
 No more than 2 prior lines of systemic chemotherapy for metastatic UC 
 Availability of tissue for biomarker analysis from an archival tissue sample or 
newly obtained core or excisional biopsy of a tumour lesion not previously ir-
radiated 
 Measureable disease 
 ECOG performance status of 0, 1, or 2 
 Adequate organ function 
 Female participants of childbearing potential have a negative urine or serum 
pregnancy test; or are surgically sterile, or willing to use two acceptable 
methods of birth control, or abstain from heterosexual activity for the course 
of the study. 
 Male participants must be willing to use an adequate method of contracep-
tion starting with the first dose of study medication. 
Exclusion  UC that is suitable for local therapy administered with curative intent 
 Currently participating in or has participated in a study of an investigational 
agent or using an investigational device (4 weeks prior to the first dose) 
 Diagnosis of immunodeficiency or receiving systemic steroid therapy or any 
other form of immunosuppressive therapy (7 days prior to the first dose) 
 Anti-cancer mAb within 4 weeks prior to study day 1 or not recovered from 
AEs due to agents administered more than 4 weeks earlier 
 Prior chemotherapy, targeted small molecule therapy, or radiation therapy 
within 2 weeks of study day 1 or not recovered from prior AEs  
 Prior therapy with all choices of active comparator 
 Known additional malignancy that is progressing or requires active treatment 
(exceptions: BCC of the skin, SCC of the skin that has undergone potentially 
curative therapy or in situ cancer; or prostate cancer that was identified fol-
lowing cystoprostatectomy for bladder cancer that is Stage T2N0M0 or lower) 
 Known active CNS metastases and/or carcinomatous meningitis 
 Active autoimmune disease requiring systemic treatment within the past 3 
months or a documented history of clinically severe autoimmune disease, or a 
syndrome that requires systemic or immunosuppressive agents 
 Active cardiac disease 
 Evidence of interstitial lung disease or active non-infectious pneumonitis 
 Active infection requiring systemic therapy 
 History of severe hypersensitivity reaction to paclitaxel, docetaxel, or to other 
drugs formulated with polysorbate 80 or polyoxyethylated castor oil, or to 
vinflunine or other vinca alkaloids 
 Requires ongoing therapy with a medication that is a strong inhibitor or in-
ducer of the cytochrome 3A4 (CYP3A4) enzymes 
 Pregnant, breastfeeding, or expecting to conceive or father children within the 
projected duration of the trial 
 Prior therapy with a PD-1 or anti-PD-Ligand 1 agent, or with an agent directed 
to another co-inhibitory T-cell receptor 
 HIV 
 Active hepatitis B or hepatitis C 
 Received a live virus vaccine within 30 days of planned start of trial treatment 
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Title: Pembrolizumab as second-line therapy for advanced urothelial carcinoma [6, 19] 
Study identifier NCT02256436, EudraCT number 2014-002009-40, KEYNOTE-045 
Analysis population 
(continuation) 
 
Characteristics 
 
Intervention 
(n = 270) 
Control 
(n = 272) 
Median age years, (range) 67 (29–88) 65 (26–84) 
Gender, n (%) ♂ 200 (74.1) 
♀ 70 (25.9) 
♂ 202 (74.3) 
♀ 70 (25.7) 
ECOG performance-status score, n (%) 
   0 
   1 
   2 
   Missing data 
 
119 (44.1) 
143 (53.0) 
2 (0.7) 
6 (2.2) 
 
106 (39.0) 
158 (58.1) 
4 (1.5) 
4 (1.5) 
Current or former smoker, n/total n (%) 165/269 (61.3) 186/269 (69.1) 
Pure transitional-cell features in histologic 
testing, n/total n (%) 186/270 (68.9) 197/270 (73.0) 
Tumour PD-L1 combined positive score ≥10%, 
n/total n (%) 
74/260 (28.5) 90/266 (33.8) 
Site of primary tumour in bladder or urethra, 
n/total n (%) 232/270 (85.9) 234/271 (86.3) 
Visceral disease, n/total n (%) 240/269 (89.2) 233/271 (86.0) 
Liver metastases, n/total n (%) 91/270 (33.7) 95/271 (35.1) 
Haemoglobin concentration <10 g/dl, n/total 
n (%) 43/262 (16.4) 44/267 (16.5) 
Number of risk factors, n (%) 
   0 
   1 
   2 
   3 or 4 
   Missing data 
 
54 (20.0) 
96 (35.6) 
66 (24.4) 
45 (16.7) 
9 (3.3) 
 
44 (16.2) 
97 (35.7) 
80 (29.4) 
45 (16.5) 
6 (2.2) 
 Completion or discontinuation of most recent 
therapy <3 months previously, n/total n (%) 
103/269 (38.3) 104/271 (38.4) 
Abbreviations: AEs = adverse events, BCC = basal cell carcinoma, CI = confidence interval, CNS = central nervous system, ECOG = Eastern 
Cooperative Oncology Group, HIV = human immunodeficiency virus, HR = hazard ratio, mAb = monoclonal antibody, PD-1 = anti-programmed 
cell death 1, SSC = squamous cell carcinoma, UC = urothelial carcinoma 
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Table 5: Risk of bias assessment on study level is based on EUnetHTA (Internal validity of randomised controlled trials) [21] 
Criteria for judging risk of bias  Risk of bias 
Adequate generation of randomisation sequence: randomisation stratified according to ECOG 
performance-status score, presence of liver metastases, haemoglobin concentration, and time 
since the last dose of chemotherapy. No evidence was found for the generation of randomisa-
tion sequence. 
unclear 
Adequate allocation concealment: Treatment assignment was not blinded. unclear 
Blinding: 
open-label 
Patient no 
Treating physician no 
Selective outcome reporting unlikely yes 
No other aspects which increase the risk of bias: industry funded the study, provided study 
drugs, and was involved in study design, data collection, analysis, interpretation, writing of 
the report; early termination of the study after the second interim analysis 
high 
Risk of bias – study level high 
Abbreviations: ECOG = Eastern Cooperative Oncology Group 
 
 
 
